AbbVie

AbbVie (NYSE: ABBV) is a global research-based biopharmaceutical company spun off from Abbott in 2013, headquartered in North Chicago, Illinois, with roughly 57,000-61,000 employees and ~$61B in 2025 net revenue. Its portfolio spans immunology (Skyrizi, Rinvoq, Humira), neuroscience (Vraylar, Botox Therapeutic), oncology, aesthetics (Botox Cosmetic, Juvederm), and eye care. Beyond drug substance it operates a large fill-finish and contract-manufacturing business (aseptic vial and prefilled-syringe filling at Barceloneta PR and Lake County, plus autoinjector packaging) across 11 U.S. sites and facilities in Italy, Ireland, Costa Rica, Germany, France and Singapore. It is in a major U.S. capacity-expansion cycle: a $1.4B AI-integrated parenteral campus in Durham NC, $380M of new API facilities in North Chicago, and the pending acquisition of West Pharmaceutical's Tempe AZ drug-delivery-device plant (on-body injector technology). The relevant AGD surface is its sterile fill-finish and drug-delivery-device assembly operations, where fragile glass containers and small injector components demand force-sensitive handling.